Neoplasm Recurrence, Local

"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.

Descriptor ID	D009364
MeSH Number(s)	C04.697.655 C23.550.727.655
Concept/Terms	Neoplasm Recurrence, Local Neoplasm Recurrence, Local Local Neoplasm Recurrences Locoregional Neoplasm Recurrence Recurrences, Local Neoplasm Neoplasm Recurrences, Local Recurrence, Local Neoplasm Recurrence, Locoregional Neoplasm Local Neoplasm Recurrence Neoplasm Recurrence, Locoregional Locoregional Neoplasm Recurrences Neoplasm Recurrences, Locoregional Recurrences, Locoregional Neoplasm

Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".

Diseases [C]
Neoplasms [C04]
Neoplastic Processes [C04.697]
Neoplasm Recurrence, Local [C04.697.655]
Pathological Conditions, Signs and Symptoms [C23]
Pathologic Processes [C23.550]
Neoplastic Processes [C23.550.727]
Neoplasm Recurrence, Local [C23.550.727.655]

Below are MeSH descriptors whose meaning is related to "Neoplasm Recurrence, Local".

Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.

Bar chart showing 126 publications over 24 distinct years, with a maximum of 13 publications in 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	4	4
2003	1	1	2
2004	3	1	4
2005	2	2	4
2006	2	2	4
2007	0	1	1
2008	1	3	4
2009	2	0	2
2010	1	1	2
2011	2	0	2
2012	2	1	3
2013	3	4	7
2014	2	1	3
2015	8	1	9
2016	5	2	7
2017	1	0	1
2018	0	1	1
2019	2	5	7
2020	4	6	10
2021	4	6	10
2022	1	11	12
2023	2	11	13
2024	4	6	10
2025	2	2	4

Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.

Gonzales Iv M, Garcia-Alcaraz C, Kaur N, Baglione AN, Livermon S, Barnes LE, Wells KJ. Improving Long-Term Adherence to Endocrine Therapy Among Breast Cancer Survivors: Development of a Multiscale Modeling and Intervention System. JMIR Cancer. 2026 Apr 30; 12:e68255.

View in: PubMed
Matsui K, Miyawaki Y, Suzuki Y, Furube T, Yoshizawa M, Toriumi T, Ebara G, Sato H, Sakuramoto S. Relationship between immune-related adverse events and long-term survival in patients treated with immune checkpoint inhibitors for unresectable advanced or recurrent esophageal cancer. Dis Esophagus. 2026 Mar 02; 39(2).

View in: PubMed
Chambers LM, Chalif J, Yao M, Reizes O, Rose PG, Michener CM, Vargas R. Gram-positive targeting antibiotics are associated with progression and death in women with platinum-sensitive recurrent high grade epithelial ovarian cancer. J Gynecol Oncol. 2026 01; 37(1):e69.

View in: PubMed
Lee HH, Siu-Li N, Pagano I, Fukui JA. Examining a Genomic Test in Predicting Extended Endocrine Benefit and Recurrence Risk in a Diverse Breast Cancer Population. Curr Oncol. 2025 Sep 25; 32(10).

View in: PubMed
Matsuo K, Enserro DM, Wright JD, Roman LD, Powell MA, Miller DS, Nagel CI, Thaker PH, Mannel RS, Stuckey AR, Guntupalli SR, Sukumvanich P, Geller MA, Vargas R, Konecny GE, Warshal DP, Tewari KS, Spirtos NM, Pothuri B, Creasman WT, Mutch DG. Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol. 2025 10; 201:184-194.

View in: PubMed
Xia K, Chen E, Hu R, Pagano I, Fukui J. Applicability of Oncotype DX Testing in a Diverse Breast Cancer Population in Hawaii. Breast J. 2025; 2025:9104103.

View in: PubMed
Ghisoni E, Benedetti F, Minasyan A, Desbuisson M, Cunnea P, Grimm AJ, Fahr N, Capt C, Rayroux N, De Carlo F, Gulhan DC, Dagher J, Barras D, Morotti M, Mar?n-Jim?nez JA, Chap BS, Santoro T, Spagnol G, Fleury M, Fortis K, Dorier J, Townsend MK, Tissot S, Rusakiewicz S, Ferreira HJ, Kraemer AI, Bassani-Stenberg M, Swisher EM, Kandalaft LA, Mastroyannis SA, Montone KT, Powell DJ, Banerjee S, Terry KL, Tworoger SS, Pittet MJ, Tanyi JL, Coukos G, Merritt MA, Fotopoulou C, Conejo-Garcia JR, Laniti DD. Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. Cancer Cell. 2025 Aug 11; 43(8):1568-1586.e10.

View in: PubMed
Jones V, Yin HH, Yuan YC, Wang Y, Li SM, Aljaber D, Sanchez A, Quinones C, Schmolze D, Yuan Y, Mortimer J, Yee L, Kruper L, Jovanovic-Talisman T, Tomsic J, Sanchez N, Chavez T, O'Regan RM, Khan QJ, Davis M, Kalinsky K, Meisel J, Kittles R, Rodriguez-Rodriguez L, Seewaldt V. Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer. Sci Rep. 2025 Feb 28; 15(1):7220.

View in: PubMed
Lobo N, Duan Z, Sood A, Zhao H, Lindskrog SV, Dyrskjot L, Giordano SH, Williams SB, Bree KK, Kamat AM. Sex Disparity in Non-muscle-invasive Bladder Cancer: Pitfalls of Large Population-based Data Sets and Lessons from an Integrated Analysis. Eur Urol Oncol. 2025 Jun; 8(3):608-611.

View in: PubMed
Yousif A, Mulla ZD, Pudar J, Elshaikh M, Khalil-Moawad R, Elshaikh MA. First-degree family history of cancers in patients with stage I endometrial carcinoma. Prevalence and prognostic impact. Arch Gynecol Obstet. 2024 Nov; 310(5):2595-2602.

View in: PubMed

People

Explore

Similar Concepts

Top Journals